Disease-A-Month
Volume 54, Issue 9 , Pages 642-670 , September 2008

Treatment of Non-Cardiac Chest Pain

References 

  1. DeMeester TR, O'Sullivan GC, Bermudez G, et al. Esophageal function in patients with angina-type chest pain and normal coronary angiograms. Ann Surg. 1982;196(4):488–498
  2. Achem SR, Kolts BE, Wears R, et al. Chest pain associated with nutcracker esophagus: a preliminary study of the role of gastroesophageal reflux. Am J Gastroenterol. 1993;88(2):187–192
  3. Stahl WG, Beton RR, Johnson CS, et al. Diagnosis and treatment of patients with gastroesophageal reflux and noncardiac chest pain. South Med J. 1994;87(7):739–742
  4. Achem SR, Kolts BE, MacMath T, et al. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci. 1997;42(10):2138–2145
  5. Chambers J, Cooke R, Anggiansah A, et al. Effect of omeprazole in patients with chest pain and normal coronary anatomy: initial experience. Int J Cardiol. 1998;65(1):51–55
  6. Flook N, Moayyedi P, Dent J, et al. Esomeprazole for treatment of unexplained chest pain in primary care: a prospective, randomized, double-blid, placebo-controlled multicenter study. Gastroenetrology. 2007;132(4):T1163;(suppl 2)
  7. Fass R, Fennerty MB, Johnson C, et al. Correlation of ambulatory 24-hour esophageal pH monitoring results with symptom improvement in patients with noncardiac chest pain due to gastroesophageal reflux disease. J Clin Gastroenterol. 1999;28(1):36–39
  8. Wong WM, Beeler J, Risner-Adler S, et al. Attitudes and referral patterns of primary care physicians when evaluating subjects with noncardiac chest pain–a national survey. Dig Dis Sci. 2005;50(4):656–661
  9. Achem S, Ferguson D, Hugl B, et al. Persistent noncardiac chest pain in patients on PPI therapy: prevalence, prescribing patterns and results of pH testing at a tertiary referral center (Abstract 48). Am J Gastroenterol. 2005;100(9):S38;(suppl)
  10. Wong W, Fass R. The proton pump inhibitor (PPI) therapeutic trial. In:  Fass R,  Eslick G editor. Noncardiac Chest Pain: A Growing Medical Problem. San Diego, CA: Plural Publish; 2007;p. 103–118
  11. Young MA, Sanowski R, Talbert G, et al. Omeprazole administration as a test for gastroesophageal reflux (abstract). Gastroenetrology. 1992;102:192
  12. Squillance S, Young MA, Sanowski R. Single dose omeprazole as a test for noncaradiac chest pain (abstract). Gastroenetrology. 1993;107:A197
  13. Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology. 1998;115(1):42–49
  14. Pandak WM, Arezo S, Everett S, et al. Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring. J Clin Gastroenterol. 2002;35(4):307–314
  15. Xia HH, Lai KC, Lam SK, et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Aliment Pharmacol Ther. 2003;17(3):369–377
  16. Bautista J, Fullerton H, Briseno M, et al. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther. 2004;19(10):1123–1130
  17. Dickman R, Emmons S, Cui H, et al. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther. 2005;22(6):547–555
  18. Ofman JJ, Gralnek IM, Udani J, et al. The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med. 1999;107(3):219–227
  19. Borzecki AM, Pedrosa MC, Prashker MJ. Should noncardiac chest pain be treated empirically? (A cost-effectiveness analysis). Arch Intern Med. 2000;160(6):844–852
  20. Cremonini F, Wise J, Moayyedi P, et al. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol. 2005;100(6):1226–1232
  21. Wang WH, Huang JQ, Zheng GF, et al. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain? (A meta-analysis). Arch Intern Med. 2005;165(11):1222–1228
  22. Schwartz MP, Wellink H, Gooszen HG, et al. Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial. Gut. 2007;56(1):20–28
  23. Annese V, Caletti G, Cipolletta L, et al. Endoscopic treatment of gastroesophageal reflux disease. Endoscopy. 2005;37(5):470–478
  24. Liu JJ, Carr-Locke DL, Osterman MT, et al. Endoscopic treatment for atypical manifestations of gastroesophageal reflux disease. Am J Gastroenterol. 2006;101(3):440–445
  25. Lundell L, Miettinen P, Myrvold HE, et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg. 2001;192(2):172–179discussion 179-81
  26. Lundell L, Miettinen P, Myrvold HE, et al. Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial (The Nordic GORD Study Group). Eur J Gastroenterol Hepatol. 2000;12(8):879–887
  27. Bammer T, Freeman M, Shahriari A, et al. Outcome of laparoscopic antireflux surgery in patients with nonerosive reflux disease. J Gastrointest Surg. 2002;6(5):730–737
  28. So JB, Zeitels SM, Rattner DW. Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplication. Surgery. 1998;124(1):28–32
  29. Chen RY, Thomas RJ. Results of laparoscopic fundoplication where atypical symptoms coexist with oesophageal reflux. Aust N Z J Surg. 2000;70(12):840–842
  30. Farrell TM, Richardson WS, Trus TL, et al. Response of atypical symptoms of gastro-oesophageal reflux to antireflux surgery. Br J Surg. 2001;88(12):1649–1652
  31. Patti MG, Molena D, Fisichella PM, et al. Gastroesophageal reflux disease (GERD) and chest pain (Results of laparoscopic antireflux surgery). Surg Endosc. 2002;16(4):563–566
  32. Rakita S, Villadolid D, Thomas A, et al. Laparoscopic Nissen fundoplication offers high patient satisfaction with relief of extraesophageal symptoms of gastroesophageal reflux disease. Am Surg. 2006;72(3):207–212
  33. Katz PO, Dalton CB, Richter JE, et al. Esophageal testing of patients with noncardiac chest pain or dysphagia (Results of three years' experience with 1161 patients). Ann Intern Med. 1987;106(4):593–597
  34. Dekel R, Pearson T, Wendel C, et al. Assessment of oesophageal motor function in patients with dysphagia or chest pain: the Clinical Outcomes Research Initiative experience. Aliment Pharmacol Ther. 2003;18(11-12):1083–1089
  35. Achem SR, Benjamin S. Esophageal dysmotility (spastic dysmotility). In:  Castell DO editors. The Esophagus. (2nd edition). Boston, MA: Little, Brown and Co; 1995;p. 247–268
  36. Richter JE, Dalton CB, Bradley LA, et al. Oral nifedipine in the treatment of noncardiac chest pain in patients with the nutcracker esophagus. Gastroenterology. 1987;93(1):21–28
  37. Achem SR. Treatment of spastic esophageal motility disorders. Gastroenterol Clin North Am. 2004;33(1):107–124
  38. Crozier RE, Glick ME, Gibb SP, et al. Acid-provoked esophageal spasm as a cause of noncardiac chest pain. Am J Gastroenterol. 1991;86(11):1576–1580
  39. Swamy N. Esophageal spasm: clinical and manometric response to nitroglycerine and long acting nitrites. Gastroenterology. 1977;72(1):23–27
  40. Pehlivanov N, Liu J, Mittal RK. Sustained esophageal contraction: a motor correlate of heartburn symptom. Am J Physiol Gastrointest Liver Physiol. 2001;281(3):G743–G751
  41. Almansa C, Wolfsen H, DeVault K, et al. Diffuse esophageal spasm: idiopathic or reflux related? (abstract). Gastroenetrology. 2008;in press
  42. Hughes J, Lockhart J, Joyce A. Do calcium antagonists contribute to gastro-oesophageal reflux disease and concomitant noncardiac chest pain?. Br J Clin Pharmacol. 2007;64(1):83–89
  43. Bortolotti M, Labriola E, Bacchelli S, et al. “Oesophageal angina” in patients with angina pectoris: a possible side effect of chronic therapy with nitroderivates and Ca-antagonists. Ital J Gastroenterol. 1992;24(7):405–408
  44. Storr M, Allescher HD, Classen M. Current concepts on pathophysiology, diagnosis and treatment of diffuse oesophageal spasm. Drugs. 2001;61(5):579–591
  45. Orlando RC, Bozymski EM. Clinical and manometric effects of nitroglycerin in diffuse esophageal spasm. N Engl J Med. 1973;289(1):23–25
  46. Shafran I, Ellison EC, Fromkes JJ, et al. Segmental esophageal spasm: a variant of diffuse esophageal spasm. Gastroenterology. 1979;44:49
  47. Parker WA, MacKinnon GL. Nitrites in the treatment of diffuse esophageal spasm. Drug Intell Clin Pharm. 1981;15(10):806–807
  48. Mellow MH. Effect of isosorbide and hydralazine in painful primary esophageal motility disorders. Gastroenterology. 1982;83(2):364–370
  49. Millaire A, Ducloux G, Marquand A, et al. Nitroglycerin and angina with angiographically normal coronary vessels (Clinical effects and effects on esophageal motility). Arch Mal Coeur Vaiss. 1989;82(1):63–68
  50. Konturek JW, Gillessen A, Domschke W. Diffuse esophageal spasm: a malfunction that involves nitric oxide?. Scand J Gastroenterol. 1995;30(11):1041–1045
  51. Preiksaitis HG, Tremblay L, Diamant NE. Nitric oxide mediates inhibitory nerve effects in human esophagus and lower esophageal sphincter. Dig Dis Sci. 1994;39(4):770–775
  52. Anand N, Paterson WG. Role of nitric oxide in esophageal peristalsis. Am J Physiol. 1994;266(1):G123–G131
  53. Murray JA, Ledlow A, Launspach J, et al. The effects of recombinant human hemoglobin on esophageal motor functions in humans. Gastroenterology. 1995;109(4):1241–1248
  54. Konturek JW, Thor P, Lukaszyk A, et al. Endogenous nitric oxide in the control of esophageal motility in humans. J Physiol Pharmacol. 1997;48(2):201–209
  55. Boger RH, Bode-Boger SM. The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol. 2001;41:79–99
  56. Bortolotti M, Brunelli F, Sarti P, et al. Clinical and manometric effects of L-arginine in patients with chest pain and oesophageal motor disorders. Ital J Gastroenterol Hepatol. 1997;29(4):320–324
  57. Bortolotti M, Mari C, Giovannini M, et al. Effects of sildenafil on esophageal motility of normal subjects. Dig Dis Sci. 2001;46(11):2301–2306
  58. Kim HS, Conklin JL, Park H. The effect of sildenafil on segmental oesophageal motility and gastro-oesophageal reflux. Aliment Pharmacol Ther. 2006;24(7):1029–1036
  59. Rhee PL, Hyun JG, Lee JH, et al. The effect of sildenafil on lower esophageal sphincter and body motility in normal male adults. Am J Gastroenterol. 2001;96(12):3251–3257
  60. Eherer AJ, Schwetz I, Hammer HF, et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut. 2002;50(6):758–764
  61. Agrawal A, Tutuian R, Hila A, et al. Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility: a case report. Dig Dis Sci. 2005;50(11):2059–2062
  62. Bortolotti M, Pandolfo N, Giovannini M, et al. Effect of Sildenafil on hypertensive lower oesophageal sphincter. Eur J Clin Invest. 2002;32(9):682–685
  63. Bassotti G, Gaburri M, Imbimbo BP, et al. Manometric evaluation of cimetropium bromide activity in patients with the nutcracker oesophagus. Scand J Gastroenterol. 1988;23(9):1079–1084
  64. Traube M, McCallum RW. Calcium-channel blockers and the gastrointestinal tract (American College of Gastroenterology's Committee on FDA related matters). Am J Gastroenterol. 1984;79(11):892–896
  65. Cohen S, Green F. The mechanics of esophageal muscle contraction (Evidence of an inotropic effect of gastrin). J Clin Invest. 1973;52(8):2029–2040
  66. de Carle DJ, Christensen J, Szabo AC, et al. Calcium dependence of neuromuscular events in esophageal smooth muscle of the opossum. Am J Physiol. 1977;232(6):E547–E552
  67. Blackwell JN, Holt S, Heading RC. Effect of nifedipine on oesophageal motility and gastric emptying. Digestion. 1981;21(1):50–56
  68. Davies HA, Lewis M, Rhodes J, et al. Nifedipine for relief of esophageal chest pain?. N Engl J Med. 1982;307(20):1274
  69. Nasrallah SM. Nifedipine in the treatment of diffuse oesophageal spasm. Lancet. 1982;2(8310):1285
  70. Nasrallah SM, Tommaso CL, Singleton RT, et al. Primary esophageal motor disorders: clinical response to nifedipine. South Med J. 1985;78(3):312–315
  71. Thomas E, Witt P, Willis M, et al. Nifedipine therapy for diffuse esophageal spasm. South Med J. 1986;79(7):847–849
  72. Davies HA, Lewis MJ, Rhodes J, et al. Trial of nifedipine for prevention of oesophageal spasm. Digestion. 1987;36(2):81–83
  73. Banciu T, Iova M, Biroasiu G, et al. The diagnostic and therapeutic contribution of calcium channel inhibitors (nifedipine) in esophageal spasm. Med Interne. 1990;28(1):69–71
  74. Traube M, Hongo M, Magyar L, et al. Effects of nifedipine in achalasia and in patients with high-amplitude peristaltic esophageal contractions. JAMA. 1984;252(13):1733–1736
  75. Richter JE, Spurling TJ, Cordova CM, et al. Effects of oral calcium blocker, diltiazem, on esophageal contractions (Studies in volunteers and patients with nutcracker esophagus). Dig Dis Sci. 1984;29(7):649–656
  76. Cattau EL, Castell DO, Johnson DA, et al. Diltiazem therapy for symptoms associated with nutcracker esophagus. Am J Gastroenterol. 1991;86(3):272–276
  77. Drenth JP, Bos LP, Engels LG. Efficacy of diltiazem in the treatment of diffuse oesophageal spasm. Aliment Pharmacol Ther. 1990;4(4):411–416
  78. Goyal RK, Rattan S. Effects of sodium nitroprusside and verapamil on lower esophageal sphincter. Am J Physiol. 1980;238(1):G40–G44
  79. Richter JE, Sinar DR, Cordova CM, et al. Verapamil: a potent inhibitor of esophageal contractions in the baboon. Gastroenterology. 1982;82(5):882–886
  80. Allen M, Mellow M, Robinson MG, et al. Comparison of calcium channel blocking agents and an anticholinergic agent on oesophageal function. Aliment Pharmacol Ther. 1987;1(2):153–159
  81. Bromm B, Meier W, Scharein E. Imipramine reduces experimental pain. Pain. 1986;25(2):245–257
  82. Peghini PL, Katz PO, Castell DO. Imipramine decreases oesophageal pain perception in human male volunteers. Gut. 1998;42(6):807–813
  83. Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66(6):355–474
  84. Kranzler JD, Gendreau JF, Rao SG. The psychopharmacology of fibromyalgia: a drug development perspective. Psychopharmacol Bull. 2002;36(1):165–213
  85. Lawson K. Tricyclic antidepressants and fibromyalgia: what is the mechanism of action?. Expert Opin Investig Drugs. 2002;11(10):1437–1445
  86. Clouse RE, Lustman PJ, Eckert TC, et al. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities (A double-blind, placebo-controlled trial). Gastroenterology. 1987;92(4):1027–1036
  87. Prakash C, Clouse RE. Long-term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci. 1999;44(12):2373–2379
  88. Cannon RO, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med. 1994;330(20):1411–1417
  89. Handa M, Mine K, Yamamoto H, et al. Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach. J Clin Gastroenterol. 1999;28(3):228–232
  90. Clouse RE. Pyschotrophic medications for the treatment of functional gastrointestinal disorders. Clin Perspect Gastroenterol. 1999;2:348–356
  91. Varia I, Logue E, O'Connor C, et al. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J. 2000;140(3):367–372
  92. Broekaert D, Fischler B, Sifrim D, et al. Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2006;23(3):365–370
  93. Rodriguez-Stanley S, Zubaidi S, Proskin HM, et al. Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity. Clin Gastroenterol Hepatol. 2006;4(4):442–450
  94. Doraiswamy PM, Varia I, Hellegers C, et al. A randomized controlled trial of paroxetine for noncardiac chest pain. Psychopharmacol Bull. 2006;39(1):15–24
  95. Achem SR. Chest pain and serotonin: a possible link?. Gastroenterology. 2001;121(2):495–496
  96. Birgisson S, Richter JE. Achalasia: what's new in diagnosis and treatment?. Dig Dis. 1997;15(suppl 1):1–27
  97. Miller LS, Parkman HP, Schiano TD, et al. Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter. Dig Dis Sci. 1996;41(10):2025–2031
  98. Miller LS, Pullela SV, Parkman HP, et al. Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal. Am J Gastroenterol. 2002;97(7):1640–1646
  99. Storr M, Allescher HD, Rosch T, et al. Treatment of symptomatic diffuse esophageal spasm by endoscopic injections of botulinum toxin: a prospective study with long-term follow-up. Gastrointest Endosc. 2001;54(6):754–759
  100. Nebendahl JC, Brand B, von Schrenck T, et al. Treatment of diffuse esophageal spasm with botulinum toxin: a prospective study with 6 months' follow up. Gastrointest Endosc. 1999;49(4):A302
  101. Cassidy MJ, Schiano TD, Adrain AL, et al. Botulinum toxin injection for the treatment of symptomatic diffuse esophageal spasm. Am J Gastroenterol. 1996;91(9):A11.P1884
  102. Lacy BE, Zayat EN, Crowell MD. Case report: botulinum toxin in hypertensive lower esophageal sphincter: a manometric case study. Dysphagia. 2002;17(1):75–80
  103. Jones MP. Botulinum toxin in hypertensive lower esophageal sphincter [Letter]. Am J Gastroenterol. 1996;91(6):1283–1284
  104. Johnson MI, Ashton CH, Thompson JW. An in-depth study of long-term users of transcutaneous electrical nerve stimulation (TENS) (Implications for clinical use of TENS). Pain. 1991;44(3):221–229
  105. Borjesson M, Pilhall M, Eliasson T, et al. Esophageal visceral pain sensitivity: effects of TENS and correlation with manometric findings. Dig Dis Sci. 1998;43(8):1621–1628
  106. Jones H, Cooper P, Miller V, et al. Treatment of non-cardiac chest pain: a controlled trial of hypnotherapy. Gut. 2006;55(10):1403–1408
  107. Eslick GD, Jones MP, Talley NJ. Non-cardiac chest pain: prevalence, risk factors, impact and consulting: a population-based study. Aliment Pharmacol Ther. 2003;17(9):1115–1124
  108. Wong WM, Lam KF, Cheng C, et al. Population based study of noncardiac chest pain in southern Chinese: prevalence, psychosocial factors and health care utilization. World J Gastroenterol. 2004;10(5):707–712
  109. van Peski-Oosterbaan AS, Spinhoven P, van der Does AJ, et al. Noncardiac chest pain: interest in a medical psychological treatment. J Psychosom Res. 1998;45(5):471–476
  110. van Peski-Oosterbaan AS, Spinhoven P, van Rood Y, et al. Cognitive-behavioral therapy for noncardiac chest pain: a randomized trial. Am J Med. 1999;106(4):424–429
  111. Klimes I, Mayou RA, Pearce MJ, et al. Psychological treatment for atypical non-cardiac chest pain: a controlled evaluation. Psychol Med. 1990;20(3):605–611
  112. Kisely S, Campbell LA, Skerritt P. Psychological interventions for symptomatic management of non-specific chest pain in patients with normal coronary anatomy. Cochrane Database Syst Rev. 2005;1:CD004101
  113. Esler JL, Bock BC. Psychological treatments for noncardiac chest pain: recommendations for a new approach. J Psychosom Res. 2004;56(3):263–269
  114. Huffman JC, Stern TA. The use of benzodiazepines in the treatment of chest pain: a review of the literature. J Emerg Med. 2003;25(4):427–437
  115. Beitman BD, Basha IM, Trombka LH, et al. Pharmacotherapeutic treatment of panic disorder in patients presenting with chest pain. J Fam Pract. 1989;28(2):177–180
  116. Beitman BD, Basha IM, Trombka LH, et al. Alprazolam in the treatment of cardiology patients with atypical chest pain and panic disorder. J Clin Psychopharmacol. 1988;8(2):127–130
  117. Wulsin LR, Maddock R, Beitman B, et al. Clonazepam treatment of panic disorder in patients with recurrent chest pain and normal coronary arteries. Int J Psychiatry Med. 1999;29(1):97–105
  118. Johansson B, Halldner L, Dunwiddie TV, et al. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci U S A. 2001;98(16):9407–9412
  119. Sylven C, Beermann B, Jonzon B, et al. Angina pectoris-like pain provoked by intravenous adenosine in healthy volunteers. Br Med J (Clin Res Ed). 1986;293(6541):227–230
  120. Rao SS, Mudipalli RS, Remes-Troche JM, et al. Theophylline improves esophageal chest pain: a randomized, placebo-controlled study. Am J Gastroenterol. 2007;102(5):930–938
  121. Achem SR. New frontiers for the treatment of noncardiac chest pain: the adenosine receptors. Am J Gastroenterol. 2007;102(5):939–941

PII: S0011-5029(08)00079-5

doi: 10.1016/j.disamonth.2008.06.008

Disease-A-Month
Volume 54, Issue 9 , Pages 642-670 , September 2008

Article Tools